C5a,Complement Component 5a
Human C5a, Tag Free (C5A-H5116) is expressed from E.coli cells. It contains AA Leu 679 - Arg 751 (Accession # P01031).
Predicted N-terminus: Met
This protein carries no "tag".
The protein has a calculated MW of 8.3 kDa. The protein migrates as 8.3 kDa under reducing (R) condition (SDS-PAGE).
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss is observed after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human C5a, Tag Free on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Human Complement Component C5a (C5a) is also known as C5,and is a protein fragment released from complement component C5.,is a potent chemotactic factor for human peripheral blood neutrophils and monocytes, and is believed to play an important role in a number of inflammatory conditions. There are several functions in the below: C5a is an anaphylatoxin, causing the release of histamine from mast cells; C5a is effective leukocyte chemoattractants, causing the accumulation of white blood cells, especially neutrophil granulocytes, at sites of complement activation; C5a activates white blood cells by increasing avidity for white blood cell integrins and upregulating the Lipoxygenase pathway for arachidonic acid metabolism; C5a is a powerful inflammatory mediator, and seems to be a key factor in the development of pathology of many inflammatory diseases involving the complement system; C5a modulates balance between activating versus inhibitory IgG Fc receptors on leukocytes, thereby enhancing autoimmune response.
- (1) Gerard, C. and N.P. Gerard, 1994, Annu. Rev. Immunol.12:775.
- (2) Monk, PN. et al., 2007, British Journal of Pharmacology. 152: 429-48.
- (3) Reis ES, et al., 2011,Brain Behav Immun. Apr 23.
- (4) Bergseth G,et al., 2011, Ann Thorac Surg., 91(2):527-33.
- (5) Manthey HD,et al., 2009, Int J Biochem Cell Biol., 41(11):2114-7.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.